Acquisition by Pepose Jay of 14964 shares of Ocuphire Pharma subject to Rule 16b-3

OCUPDelisted Stock  USD 1.13  0.06  5.04%   
Slightly above 62% of Ocuphire Pharma's investor base is looking to short. The analysis of current outlook of investing in Ocuphire Pharma suggests that many traders are alarmed regarding Ocuphire Pharma's prospects. Ocuphire Pharma's investing sentiment overview a quick insight into current market opportunities from investing in Ocuphire Pharma. Many technical investors use Ocuphire Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Ocuphire Pharma Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Ocuphire insider trading alert for grant of common stock by Pepose Jay, the corporate stakeholder, on 3rd of January 2024. This event was filed by Ocuphire Pharma Inc with SEC on 2024-01-03. Statement of changes in beneficial ownership - SEC Form 4

Ocuphire Pharma Fundamental Analysis

We analyze Ocuphire Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocuphire Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocuphire Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Net Asset

Net Asset Comparative Analysis

Ocuphire Pharma is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Ocuphire Pharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ocuphire Pharma stock to make a market-neutral strategy. Peer analysis of Ocuphire Pharma could also be used in its relative valuation, which is a method of valuing Ocuphire Pharma by comparing valuation metrics with similar companies.

Peers

Ocuphire Pharma Related Equities

CGTXCognition Therapeutics   13.05   
0%
65.0%
RNAZTranscode Therapeutics   12.22   
0%
61.0%
RVPHReviva Pharmaceuticals   11.90   
0%
59.0%
FBIOPFortress Biotech   7.27   
0%
36.0%
CKPTCheckpoint Therapeutics   2.04   
0%
10.0%
EYPTEyepoint Pharmaceuticals   1.18   
5.0%
0%
PLXProtalix Biotherapeutics   1.64   
8.0%
0%
FBIOFortress Biotech   1.89   
9.0%
0%
MBIOMustang Bio   2.11   
10.0%
0%
RIGLRigel Pharmaceuticals   5.01   
25.0%
0%
KODKodiak Sciences   10.60   
52.0%
0%
SLSSellas Life   13.89   
69.0%
0%
RVPHWReviva Pharmaceuticals   20.02   
100.0%
0%
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Consideration for investing in Ocuphire Stock

If you are still planning to invest in Ocuphire Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ocuphire Pharma's history and understand the potential risks before investing.
CEOs Directory
Screen CEOs from public companies around the world
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Technical Analysis
Check basic technical indicators and analysis based on most latest market data